EMACO方案在妊娠滋养细胞肿瘤中的应用效果及对疾病相关血液指标的影响  

Application Effect of EMACO Regimens in Gestational Trophoblastic Neoplasia and Influence on Disease-related Blood Indexes

作　　者：方堃[1] 覃庆锋[1] 邱芳[1] 邓丹妮 丁娅妮 FANG Kun;QIN Qingfeng;QIU Fang;DENG Danni;DING Yani(Guizhou Provincial People's Hospital,Guiyang 550001,China)

机构地区：[1]贵州省人民医院,贵州贵阳550001

出　　处：《中国医学创新》2023年第10期1-4,共4页Medical Innovation of China

基　　金：2021年贵州省省级科技计划项目(黔科合支撑[2021]一般040)。

摘　　要：目的:探究EMACO方案在妊娠滋养细胞肿瘤中的应用效果及对疾病相关血液指标的影响。方法:将2019年9月-2021年12月贵州省人民医院收治的82例妊娠滋养细胞肿瘤患者根据随机数字表法分为对照组和观察组,各41例。对照组采用5-FU方案治疗,观察组采用EMACO方案治疗。比较两组的治疗总有效率、不良反应发生率、治疗前后基质金属蛋白酶(MMP)相关指标[MMP-2、基质金属蛋白酶抑制剂2(TIMP-2)]、人绒毛膜促性腺激素β(β-hCG)、p53抗体及妊娠相关血浆蛋白A(PAPP-A)。结果:观察组的治疗总有效率显著高于对照组,各类不良反应发生率均显著低于对照组,差异均有统计学意义(P<0.05);治疗前两组疾病相关血液指标比较,差异均无统计学意义(P>0.05),治疗1、3个疗程后,观察组疾病相关血液指标均显著低于对照组,差异均有统计学意义(P<0.05)。结论:EMACO方案在妊娠滋养细胞肿瘤中的疗效较好,安全性较高,且可有效控制疾病相关血液指标水平,因此在妊娠滋养细胞肿瘤患者中的应用价值较高。Objective:To investigate the application effect of EMACO regimens in gestational trophoblastic neoplasia and influence on disease-related blood indexes.Method:A total of 82 patients with gestational trophoblastic neoplasia who were admitted to Guizhou Provincial People's Hospital from September 2019 to December 2021 were divided into the control group and the observation group according to the random number table method,with 41 cases in each group.The control group was treated with 5-FU regimen,and the observation group was treated with EMACO regimen.The total effective rate,incidence of adverse reactions,matrix metalloproteinase(MMP)related indexes[MMP-2,tissue inhibitor of matrix metalloproteinases 2(TIMP-2)],human chorionic gonadotropinβ(β-hCG),p53 antibody and pregnancy associated plasma protein-A(PAPP-A)before and after treatment were compared between the two groups.Result:The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the incidences of various adverse reactions were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the disease-related blood indexes between the two groups(P>0.05).After 1,3 courses of treatment,the disease-related blood indexes in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:EMACO regimen is effective and safe in the treatment of gestational trophoblastic neoplasia,and can effectively control the level of disease-related blood indexes,so it has high application value in patients with gestational trophoblastic neoplasia.

关 键 词：妊娠滋养细胞肿瘤 EMACO方案 基质金属蛋白酶 

分 类 号：R737.33[医药卫生—肿瘤]